The next phase of the obesity drug race
US$ 21.61
tirzepatide cvot trial In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT results: https://nej.md/4qd5rLx SURPASS-CVOT trial: For patients with
Description
Stories about medicine safety in the U.S
Best way to start your GLP-1+GIP weight loss journey
Mounjaro dosage and schedule
Novo Nordisk is evaluating a long-acting semaglutide implant designed to keep GLP-1 patients on treatment for months at a time and food and drink manufacturers should be watching closely.
Avoid freezing
Radcliff, KY
